Feedback
Settings

Settings

Goto Application

3,545 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 355
1.20250205330METHODS FOR PROVIDING PROTECTION TO PORCINE EPIDEMIC DIARRHEA VIRUS (PEDV) WITH A PLANT PRODUCED VACCINE
US - 26.06.2025
Int.Class A61K 39/225
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
225Porcine transmissible gastroenteritis virus
 Appl.No 18989993 Applicant Mazen Animal Health, Inc. Inventor John Howard

Methods for producing a protective immune response to Porcine Epidemic Diarrhea Virus (PEDV) is provided wherein a fusion protein comprising the S1 Spike protein of the virus operably fused to the heat labile enterotoxin B subunit (LTB) peptide is expressed in a plant and the plant or plant product comprising the fusion protein is orally administered to an animal. The vaccine can be produced by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleic acid encoding the S1-LTB fusion protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. When orally administered to an animal, a protective response is observed, including a serum antibody response and mucosal immune response.

2.WO/2025/127075SURFACE-MODIFIED IRON OXIDE NANOPARTICLES AND VACCINE AGAINST SARS-COV-2 CONTAINING SAID SURFACE-MODIFIED IRON OXIDE NANOPARTICLES
WO - 19.06.2025
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/JP2024/043877 Applicant TOHOKU UNIVERSITY Inventor SATO Ko
The problem addressed is to provide surface-modified iron oxide nanoparticles for use in a vaccine exhibiting an infection preventive effect on SARS-CoV-2.　The problem can be solved by surface-modified iron oxide nanoparticles comprising SARS-CoV-2 spike protein and iron oxide nanoparticles, where the spike protein of SARS-CoV-2 is bound to the surface of the iron oxide nanoparticles.
3.120098946冠状病毒
CN - 06.06.2025
Int.Class C12N 7/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
 Appl.No 202411677449.1 Applicant 皮尔布莱特研究所 Inventor E·比克顿
本发明提供了活的减毒冠状病毒，其包含编码多聚蛋白的变体复制酶基因，所述多聚蛋白包含在非结构蛋白（nsp）‑10、nsp‑14、nsp‑15或nsp‑16之一个或多个中的突变。所述冠状病毒可以用作疫苗用于治疗和/或预防受试者中的疾病（例如传染性支气管炎）。
4.120098149一种广谱抑制新型冠状病毒的重组多肽及其应用
CN - 06.06.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 202510593359.2 Applicant 浙江大学杭州国际科创中心 Inventor 毕稳稳
本发明公开了一种广谱抑制新型冠状病毒的重组多肽及其应用，涉及合成生物与医药领域。所述重组多肽是由来源于ACE2的多肽和来源于新型冠状病毒HR2的多肽通过连接子连接而成，其中来源于ACE2的多肽引入了6个氨基酸突变（AKT/VEW和NHE/DIQ），以提高其与RBD的相互作用。本发明所述的重组多肽具有高效广谱抗新型冠状病毒的活性，可用于制备开发抗新型冠状病毒的药物。本发明提供的重组多肽可高效抑制新型冠状病毒及其多种突变株，可用于制备预防或治疗冠状病毒的药物组合物，有潜力发展成为广谱抗冠状病毒的药物，以最大限度遏制现有冠状病毒和未来可能新发与再现冠状病毒的流行。
5.120098150一种广谱抗新型冠状病毒的双靶点多肽及其应用
CN - 06.06.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 202510593361.X Applicant 浙江大学杭州国际科创中心 Inventor 毕稳稳
本发明公开了一种广谱抗新型冠状病毒的双靶点多肽及其应用，涉及生物医药领域。本发明提供的多肽药物通过同时作用于病毒的RBD和HR1两个关键靶点，能够更有效地协同抑制病毒的感染过程。一方面，通过靶向RBD，可以阻断病毒与宿主细胞的结合，从而阻碍病毒在宿主细胞表面吸附的现象，遏制其吸附进程；另一方面，通过靶向HR1，可以干扰病毒6‑HB的形成，进一步抑制病毒包膜与宿主包膜的融合过程。本发明提供的能够同时靶向于新型冠状病毒RBD和HR1双靶点的多肽，尤其是R1L25HR2，其能够有效抑制SARS‑CoV‑2及其突变株，具有广谱抗新型冠状病毒的活性。
6.120098932稳定表达PED病毒核衣壳蛋白截断片段的IPEC-J2细胞株及其应用
CN - 06.06.2025
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
 Appl.No 202510227522.3 Applicant 浙江大学 Inventor 李肖梁
本发明涉及生物工程技术，旨在提供一种稳定表达PED病毒核衣壳蛋白截断片段的IPEC‑J2细胞株及其应用。该细胞株保藏于中国典型培养物保藏中心，保藏名称为猪小肠上皮细胞系R58‑WT‑IPEC，拉丁文名为Sus scrofa，保藏编号为CCTCC NO：C202425。本发明揭示了PEDV N蛋白在病毒复制阶段的关键作用，并提出将其作为靶点应用于调控PEDV感染。与野生型IPEC‑J2细胞系相比，该细胞株促进作用显著，能够解决PEDV在IPEC‑J2细胞系中增殖较差的问题，进一步提升了IPEC‑J2细胞系在病毒分离、扩繁中应用的可能性。
7.120082601一种低复制能力的猪流行性腹泻病毒及其构建方法和应用
CN - 03.06.2025
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No 202510578990.5 Applicant 江苏省农业科学院 Inventor 李彬
本发明公开了一种低复制能力的猪流行性腹泻病毒及其构建方法和应用，涉及生物医药技术领域。该构建方法包括将猪流行性腹泻病毒AH2012/12的S蛋白的第1347和1348位氨基酸突变成丝氨酸，构建得到重组病毒的步骤；该重组病毒即为低复制能力的猪流行性腹泻病毒。本发明通过评估该重组病毒的免疫原性，结果显示重组病毒能诱导产生高水平的PEDV S蛋白IgG抗体和中和抗体，且产生抗体水平在免疫28天后超过其亲本毒株AH2012/12。这些结果说明重组病毒的2个棕榈酰化修饰位点能让抗体水平升高，是减弱病毒复制能力的重要靶点。本发明为猪流行性腹泻病毒减毒新疫苗研发奠定了重要基础。
8.120081914一种HLA-C限制性SARS-CoV-2淋巴细胞抗原表位肽及其应用
CN - 03.06.2025
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 202510010983.5 Applicant 中国人民解放军军事科学院军事医学研究院 Inventor 李敏
本发明公开了一种HLA‑C限制性SARS‑CoV‑2淋巴细胞抗原表位肽及其应用，属于医学免疫学和感染病学领域，特别涉及一种SARS‑CoV‑2的3种胸腺依赖性淋巴细胞抗原表位肽，所述表位肽其氨基酸序列为：SEQ ID NO:1～3任一所示；或者，在SEQ ID NO:1～3任一序列中取代、缺失、插入和/或添加有1个或多个氨基酸序列所获得的氨基酸序列。所述抗原表位肽可以被HLA‑C0101和HLA‑C0602分子所提呈，刺激SARS‑CoV‑2特异性胸腺依赖性淋巴细胞活化、增殖和分化，从而发挥抗SARS‑CoV‑2感染的免疫效应作用；这些抗原肽可以用来制备SARS‑CoV‑2的混合多肽疫苗、串联多个表位肽的重组蛋白疫苗以及DNA和RNA疫苗，可以用来制备检测SARS‑CoV‑2特异性胸腺依赖性淋巴细胞的检测试剂盒，也可以用来制备治疗SARS‑CoV‑2感染的效应性胸腺依赖性淋巴细胞或药物，在SARS‑CoV‑2感染及COVID‑19的预防、治疗和诊断中有着潜在的应用价值。
9.2025517238多重エピトープ構築物
JP - 03.06.2025
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 2025512200 Applicant イーザアールエヌーエー　イムノセラピーズ　エンヴェー Inventor ブランコ　マデイラ，フィリペ
本発明は、ワクチン接種療法の分野に位置付けられる。より詳細には、本発明は、コロナウイルス由来のペプチド又はその機能的バリアント及び断片をコードする核酸配列を含む多重エピトープ構築物に関する。本発明は、さらに、対象におけるコロナウイルス、特にSARS-CoV-2ウイルスの処置又は防止に使用される組合せ、ポリペプチド、又は医薬組成物に関する。
【選択図】なし
10.320523COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF
IL - 01.06.2025
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No 320523 Applicant HELIX NANOTECHNOLOGIES INC Inventor
# -